---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-015199"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2024-04-18T23:59:59+00:00"
generated_at: "2026-06-03T18:20:13.549557+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MyMD CSO Dr. Adam Kaplin resigns effective immediately; no disagreement cited

## Summary
- Dr. Adam Kaplin resigned as Chief Scientific Officer on April 15, 2024, effective immediately.
- Resignation not due to any disagreement with the company, management, or board.
- No replacement named; company's future CSO plans are undisclosed.

## SEC filing metadata
- accession: 0001493152-24-015199
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2024-04-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315224015199/0001493152-24-015199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315224015199/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-015199
- JSON: https://secwatch.observer/filing/0001493152-24-015199.json
- Plain text: https://secwatch.observer/filing/0001493152-24-015199.txt

## Key facts
- Executive change
  Adam Kaplin resigned as Chief Scientific Officer at Q/C TECHNOLOGIES, INC..
  - Action: resigned
  - Role: Chief Scientific Officer
  source text: On April 15, 2024, Adam Kaplin, M.D., Ph.D., who served as Chief Scientific Officer of MyMD Pharmaceuticals, Inc. (the “Company”), tendered his resignation from his role as an officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321834/000149315224015199/0001493152-24-015199-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.